In a patient with blood pressure 130‑151/87‑93 mm Hg while taking lisinopril‑hydrochlorothiazide 20 mg/12.5 mg daily and famotidine (Pepcid) 20 mg daily, what is the appropriate next step to achieve a target below 130/80 mm Hg?

Intensify Blood Pressure Therapy by Adding a Third Agent

Your patient's blood pressure remains above target (130-151/87-93 mm Hg) on lisinopril-hydrochlorothiazide 20-12.5 mg daily, so you should add a third antihypertensive medication—specifically a calcium channel blocker (amlodipine 5-10 mg daily) or increase to a higher-dose combination if available.

Current Situation Analysis

Your patient is on a standard two-drug combination (ACE inhibitor + thiazide diuretic) but has not achieved the target blood pressure of <130/80 mm Hg recommended by current guidelines 1, 2, 3. The systolic readings of 130-151 mm Hg and diastolic readings of 87-93 mm Hg indicate Grade 1 hypertension that requires intensification.

The famotidine (Pepcid) does not significantly affect blood pressure and is not contributing to the problem 4.

Target Blood Pressure

• ACC/AHA 2022 and 2025 guidelines: Target <130/80 mm Hg for most adults with hypertension 1, 2
• ESC/ISH 2020 guidelines: Initial target <140/90 mm Hg, then <130/80 mm Hg if tolerated 5, 3
• Your patient needs further reduction: Currently 0-21 mm Hg above systolic target and 7-13 mm Hg above diastolic target

Recommended Treatment Algorithm

Step 1: Add a Third Agent (Preferred Approach)

Add a dihydropyridine calcium channel blocker as the third-line agent 5:

• Amlodipine 5 mg daily initially, can increase to 10 mg daily if needed
• Alternative: Nifedipine extended-release or other long-acting DHP-CCB

This follows the standard three-drug regimen recommended by ISH 2020 guidelines: ACE inhibitor/ARB + thiazide diuretic + calcium channel blocker 5.

Step 2: If Three Drugs Fail to Control BP

If blood pressure remains uncontrolled after 3 months on three drugs at adequate doses, add:

• Spironolactone 25 mg daily (preferred fourth-line agent) 5
• Alternatives if spironolactone contraindicated: amiloride, doxazosin, eplerenone, or beta-blocker 5

Alternative Approach: Maximize Current Combination

You could consider switching to lisinopril-hydrochlorothiazide 20-25 mg (doubling the HCTZ dose), though this is less preferred than adding a third drug class 6, 7. The higher HCTZ dose provides additional blood pressure reduction but increases risk of hypokalemia and metabolic side effects 4.

Timeline and Monitoring

• Achieve target BP within 3 months of treatment intensification 1, 5
• Follow-up in 1 month after adding the third agent to assess response and tolerability 1
• Monitor serum potassium and creatinine within 2-4 weeks after medication changes, especially given the ACE inhibitor 4
• Once at goal, follow up every 3-6 months 1

Important Considerations

Check Medication Adherence First

Before intensifying therapy, confirm the patient is taking lisinopril-HCTZ daily as prescribed. Non-adherence is a common cause of apparent treatment resistance 5.

Lifestyle Modifications

Reinforce:

• Sodium restriction (<2 grams/day)
• Weight loss if overweight (BMI data shows obese patients may have greater nocturnal BP elevations) 8
• Regular physical activity
• Alcohol moderation
• DASH diet pattern 1, 2

Avoid Common Pitfalls

1. Do not add an ARB to the ACE inhibitor: Dual RAS blockade increases risk of hyperkalemia, hypotension, and acute kidney injury without additional cardiovascular benefit 4

2. Do not use non-dihydropyridine CCBs (diltiazem, verapamil) if there is any history of heart failure, as they have negative inotropic effects 9

3. Monitor for ACE inhibitor side effects: The patient should report any cough, angioedema symptoms (facial/tongue swelling), or lightheadedness 4

4. Avoid NSAIDs: These can blunt the antihypertensive effect of ACE inhibitors and worsen renal function 4

When to Refer to Hypertension Specialist

Refer if 5:

• Blood pressure remains uncontrolled on three drugs including a diuretic
• Suspicion of secondary hypertension
• Significant renal impairment develops (eGFR <30 mL/min/1.73m²)
• Resistant hypertension requiring four or more agents

Evidence Quality Note

The recommendation to add a calcium channel blocker as third-line therapy is based on consistent guideline recommendations from multiple international societies (ISH 2020, ESC 2024, ACC/AHA 2022-2025) 1, 5, 2, 3. This stepwise approach has been validated in multiple clinical trials showing cardiovascular risk reduction with intensive blood pressure control to <130/80 mm Hg 1, 2.